Eisai Ceo Haruo Naito
Pharma
Tata Main Hospital.
Russian Federation
Biography
The move to work with Moscow-based PharmStandard follows an arrangement with Dr. Reddy's Laboratories in India over development rights for a Phase II Eisai oncology candidate E7777. The deals signal that Eisai is increasingly comfortable looking to emerging market drug firms as it seeks to aim resources at promising cancer candidates while scaling down other efforts--such as on weight-loss drug Belviq (lorcaserin HCl)--and scales up production at its India API plant in Andhra Pradesh
Research Interest
Pharmacology, Pharmaceutics, biotechnology and in the field of medicine
